On the one hand, the downregulation of RIPK3 or MLKL is related to poor prognosis of various types of cancer, such as breast cancer, colorectal cancer, acute myeloid leukemia, head and neck squamous cell carcinoma, melanoma, cervical squamous cell carcinoma, gastric cancer, and ovarian cancer. Here, MLKL is linked to acute myeloid leukemia.